The Oncotype DX Breast Recurrence Score® (hereinafter referred to as ODXRS) test is used in clinical practice to predict the benefit of adjuvant CHT in ER positive/HER2 negative, lymph node (LN)-negative or up to three LN-positive early-stage BC disease. Here, ERBB2 is linked to breast cancer.